期刊文献+

血管钠肽抑制心肌增殖与机制的研究 被引量:2

The effects and mechanism of VNP attenuates myocardial proliferation
下载PDF
导出
摘要 应用 NE、低氧或佛波酯 (PMA)等方法刺激心肌细胞和心成纤维细胞的增殖 ,实验证明血管钠肽对增殖有抑制作用 ,它通过升高细胞内 c GMP和降低细胞内 Ca2 + 浓度等发挥作用 ,对肺动脉平滑肌细胞的增殖也有抑制作用 ,表明 VNP对心肌细胞、心成纤维细胞和肺动脉平滑肌细胞有负调控作用 。 The proliferation of cardiac myocytes and cardiac fibroblasts induced by norepinephrine or hypoxia or phorbol 12 myristate 13 acetate(PMA),vasonatrin peptide(VNP) dose dependently inhibit their growth promating effects,which may be associated with the elevation of intracellular level of cGMP and decrease of intracellular calcium,VNP has also inhibitory effect on the proliferation of pulmonary artery smooth cells,results suggest that VNP has negative regulatory action on the gorwth of cardiac myocytes,cardiac fibroblasts and vascular smooth muscle cells,VNP possess preventable and theapeutic effects on cardiac hypertrophy and hypoxic pulmonary hypertension.
出处 《心脏杂志》 CAS 2002年第5期374-376,共3页 Chinese Heart Journal
基金 国家自然科学基金资助项目 (No.3 9970 3 2 7)
关键词 血管钠肽 心肌增殖 抑制 机制 心肌肥大 低氧性肺动脉高压 预防 治疗 vasonatrin peptide proliferation inhibition mechanism
  • 相关文献

参考文献14

二级参考文献14

  • 1吴建明,唐朝枢.血管活性多肽对心肌细胞和血管平滑肌细胞增殖的影响[J].生理科学进展,1993,24(1):29-32. 被引量:2
  • 2Liu Q Y,J Pharmacol Exp Ther,1994年,2卷,271期,935页
  • 3Arjona A A,Gen Pharmacol,1997年,28卷,3期,387页
  • 4司徒镇强,细胞培养,1996年,186页
  • 5Wei C M,J Clin Invest,1993年,92卷,2048页
  • 6Feng H S,心功能杂志,1998年,10卷,2期,69页
  • 7Liu Q Y,J Pharmacol Exp Ther,1994年,271卷,2期,935页
  • 8Wei C M,J Clin Invest,1993年,92卷,4期,2048页
  • 9Cao L,Hypertension,1995年,25卷,2期,227页
  • 10Wei C M,J Clin Invest,1993年,92卷,4期,2048页

共引文献20

同被引文献21

  • 1Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase[J]. Proc Natl Acad Sci USA,1994,91(16): 7583-7587.
  • 2Lincoln TM, Dey N, Sellak H. cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression[J]. J Appl Physiol,2001,91(3):1421-1430.
  • 3Mann JM, McIntosh CL, Roberts WC. Spasm of saphenous veins used as conduits for aortocoronary bypass grafting[J]. Am J Cardiol,1987,59(9): 1000-1002.
  • 4Lakshminrusimha S, D'Angelis CA, Russell JA, et al. C-type natriuretic peptide system in fetal ovine pulmonary vasculature[J]. Am J Physiol Lung Cell Mol Physiol,2001,281(2):L361-L368.
  • 5Wei CM, Kim CH, Khraibi AA, et al. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro[J]. Hypertension,1994, 23(6):903-907.
  • 6Wei CM, Kim CH, Miller VM, et al. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide[J]. J Clin Inves,1993,92(4): 2048-2052.
  • 7Cao L, Zlock DW, Gardner DG. Differential regulation of natriuretic peptide receptor activity in vascular cells[J]. Hypertension,1994,24(3): 329-338.
  • 8郑永芳 王国勇 见:韩启德 文允镒主编.细胞膜钙通道与钾通道[A].见:韩启德,文允镒主编.血管生物学:第1版[C].北京:北京医科大学出版社,1997.52—60.
  • 9Mehran M,Yuan-Cheng B,Fung WH,et al.Cellular and molecular mechanisms of pulmonary vascular remodeling:role in the development of pulmonary hypertension[J].Microvasc Res,2004,(68):75-103.
  • 10Marc H,Nicholas WM,Stephen LA,et al.Cellular and molecular pathobiology of pulmonary arterial hypertension[J].J Am Coll Cardiol,2004,43(12):13S-24S.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部